Literature DB >> 9257848

Cytotoxic CD8+ T cells recognize EBV antigen but poorly kill autologous EBV-infected B lymphoblasts: immunodominance is elicited by a peptide epitope that is presented at low levels in vitro.

Y Shi1, K D Smith, M G Kurilla, C T Lutz.   

Abstract

CD8+ T cells play a crucial role in surveillance against EBV-associated malignancies. EBV-specific T cells traditionally have been identified by their ability to kill autologous EBV-transformed B lymphoblastoid cell lines (LCL). Here we report CD8+ cloned and bulk T cells that specifically recognize EBV nuclear Ag EBNA-3C, but do not efficiently kill autologous or HLA-matched LCL. The low cytolysis of these T cells was due to the extremely low density of the antigenic epitope (LDFVRFMGV, EBNA-3C amino acids 285-293) on autologous LCL. The T cells efficiently killed target cells in the presence of < 1 pM synthetic EBNA-3C peptide and, therefore, recognize peptide/HLA complexes with high avidity. Donor T cells with this phenotype were stimulated by autologous LCL and dominated the in vitro EBV-specific response. This indicates that low abundance viral peptides can induce a dominant T cell response.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9257848

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  9 in total

1.  Endoplasmic reticulum aminopeptidase 1 (ERAP1) trims MHC class I-presented peptides in vivo and plays an important role in immunodominance.

Authors:  Ian A York; Michael A Brehm; Sophia Zendzian; Charles F Towne; Kenneth L Rock
Journal:  Proc Natl Acad Sci U S A       Date:  2006-06-05       Impact factor: 11.205

2.  Identification of a cytotoxic T-lymphocyte response to the novel BARF0 protein of Epstein-Barr virus: a critical role for antigen expression.

Authors:  N Kienzle; T B Sculley; L Poulsen; M Buck; S Cross; N Raab-Traub; R Khanna
Journal:  J Virol       Date:  1998-08       Impact factor: 5.103

3.  Use of interferon-γ enzyme-linked immunospot assay to characterize novel T-cell epitopes of human papillomavirus.

Authors:  Xuelian Wang; William W Greenfield; Hannah N Coleman; Lindsey E James; Mayumi Nakagawa
Journal:  J Vis Exp       Date:  2012-03-08       Impact factor: 1.355

4.  Primary CD4+ T-cell responses provide both helper and cytotoxic functions during Epstein-Barr virus infection and transformation of fetal cord blood B cells.

Authors:  Georgina J MacArthur; A Douglas Wilson; Martin A Birchall; Andrew J Morgan
Journal:  J Virol       Date:  2007-02-21       Impact factor: 5.103

5.  Cytolytic CD4(+)-T-cell clones reactive to EBNA1 inhibit Epstein-Barr virus-induced B-cell proliferation.

Authors:  Sarah Nikiforow; Kim Bottomly; George Miller; Christian Münz
Journal:  J Virol       Date:  2003-11       Impact factor: 5.103

6.  Simultaneous assessment of cytotoxic T lymphocyte responses against multiple viral infections by combined usage of optimal epitope matrices, anti- CD3 mAb T-cell expansion and "RecycleSpot"

Authors:  Florian K Bihl; Elisabetta Loggi; John V Chisholm; Hannah S Hewitt; Leah M Henry; Caitlyn Linde; Todd J Suscovich; Johnson T Wong; Nicole Frahm; Pietro Andreone; Christian Brander
Journal:  J Transl Med       Date:  2005-05-11       Impact factor: 5.531

Review 7.  Epstein-Barr virus and multiple sclerosis: potential opportunities for immunotherapy.

Authors:  Michael P Pender; Scott R Burrows
Journal:  Clin Transl Immunology       Date:  2014-10-31

8.  Decreased T cell reactivity to Epstein-Barr virus infected lymphoblastoid cell lines in multiple sclerosis.

Authors:  M P Pender; P A Csurhes; A Lenarczyk; C M M Pfluger; S R Burrows
Journal:  J Neurol Neurosurg Psychiatry       Date:  2008-11-17       Impact factor: 10.154

9.  The B subunit of Escherichia coli heat-labile enterotoxin enhances CD8+ cytotoxic-T-lymphocyte killing of Epstein-Barr virus-infected cell lines.

Authors:  Kong-Wee Ong; A Douglas Wilson; Timothy R Hirst; Andrew J Morgan
Journal:  J Virol       Date:  2003-04       Impact factor: 5.103

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.